We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Outlook for 2015: Antitrust Litigation in the Pharma Industry—More Than Just Actavis Progeny

05 March 2015

BNA Insights

In 2014 there were a number of significant antitrust developments related to litigation in the pharmaceutical industry. These involved not only pharmaceutical patent litigation settlements (so-called "reverse payment" agreements), but also conduct related to product reformulations and Risk Evaluation and Mitigation Strategies activity.

Read More: Outlook for 2015: Antitrust Litigation in the Pharma Industry—More Than Just Actavis Progeny

The team

Loading data